BIO-RAD LABORATORIES, INC.
Data quality: 100%
BIO-B
NYSE
Manufacturing
Measuring & Analyzing Instruments
$277.00
$0.00
(0.00%)
Mkt Cap: 7.48 B
Price
$277.00
Mkt Cap
7.48 B
Day Range
$277.00 — $277.00
52-Week Range
$225.29 — $321.12
Volume
3
Open $277.00
50D / 200D Avg
$279.39
0.85% below
50D / 200D Avg
$280.40
1.21% below
Quick Summary
Key Takeaways
Revenue declined -3.04% annually over 5 years
ROE of 10.96% — decent returns on equity
Net margin of 29.42% shows strong profitability
Debt/Equity of 0.18 — conservative balance sheet
Generating 374.60 M in free cash flow
P/E of 9.84 — trading at a low valuation
Growth
Revenue Growth (5Y)
-3.04%
Below sector avg (1.82%)
Revenue (1Y)0.65%
Earnings (1Y)N/A
FCF Growth (3Y)31.01%
Quality
Return on Equity
10.96%
Above sector avg (-53.47%)
ROIC0.38%
Net Margin29.42%
Op. Margin1.83%
Safety
Debt / Equity
0.18
Below sector avg (0.31)
Current Ratio5.44
Interest Coverage0.96
Valuation
PE (TTM)
9.84
Above sector avg (-1.47)
P/B Ratio1.11
EV/EBITDA38.96
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 9.8 | -1.5 |
| P/B | 1.1 | 1.6 |
| ROE % | 11.0 | -53.5 |
| Net Margin % | 29.4 | -41.5 |
| Rev Growth 5Y % | -3.0 | 1.8 |
| D/E | 0.2 | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0.65% | Revenue Growth (3Y) | -1.66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -3.04% | Earnings Growth (5Y) | -34.96% |
| Profitability | |||
| Revenue (TTM) | 2.58 B | Net Income (TTM) | 759.90 M |
| ROE | 10.96% | ROA | 7.63% |
| Gross Margin | 51.87% | Operating Margin | 1.83% |
| Net Margin | 29.42% | Free Cash Flow (TTM) | 374.60 M |
| ROIC | 0.38% | FCF Growth (3Y) | 31.01% |
| Safety | |||
| Debt / Equity | 0.18 | Current Ratio | 5.44 |
| Interest Coverage | 0.96 | Asset Turnover | 0.26 |
| Working Capital | 2.32 B | Tangible Book Value | 5.77 B |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 9.84 | Forward P/E | N/A |
| P/B Ratio | 1.11 | P/S Ratio | 2.89 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 38.96 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 5.01% | ||
| Market Cap | 7.48 B | Enterprise Value | 8.28 B |
| Per Share | |||
| EPS (Diluted TTM) | 27.85 | Revenue / Share | 95.71 |
| FCF / Share | 13.88 | OCF / Share | 19.72 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | -33.28% |
| EPS CAGR (10Y) | 45.55% | ||
| Efficiency | |||
| CapEx / Revenue | 6.10% | FCF Conversion | 49.30% |
| SBC-Adj. FCF | 316.90 M | Growth Momentum | 3.69 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.58 B | 2.57 B | 2.67 B | 2.80 B | 2.92 B |
| Net Income | 759.90 M | -1.84 B | -637.32 M | -3.63 B | 4.25 B |
| EPS (Diluted) | 27.85 | -25.57 | -21.82 | -121.79 | 140.56 |
| Gross Profit | 1.34 B | 1.38 B | 1.43 B | 1.57 B | 1.64 B |
| Operating Income | 47.20 M | 269.00 M | 337.80 M | 482.62 M | 489.43 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 275.60 M | 295.90 M | 247.43 M | 256.89 M | 271.66 M |
| SG&A Expenses | 844.30 M | 814.00 M | 841.72 M | 827.83 M | 879.57 M |
| D&A | 165.40 M | 151.60 M | 145.90 M | 137.30 M | 133.80 M |
| Interest Expense | 49.00 M | 48.90 M | 49.44 M | 38.11 M | 1.55 M |
| Income Tax | 235.60 M | -498.30 M | -212.78 M | -1.08 B | 1.19 B |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10.58 B | 9.36 B | 12.30 B | 13.50 B | 17.78 B |
| Total Liabilities | 3.12 B | 2.79 B | 3.56 B | 3.89 B | 4.11 B |
| Shareholders' Equity | 7.45 B | 6.57 B | 8.74 B | 9.62 B | 13.67 B |
| Total Debt | 1.20 B | 1.21 B | 1.21 B | — | — |
| Cash & Equivalents | 529.80 M | 488.10 M | 403.82 M | 434.22 M | 470.78 M |
| Current Assets | 2.91 B | 3.03 B | 3.05 B | 3.16 B | 1.99 B |
| Current Liabilities | 517.00 M | 467.80 M | 522.80 M | 568.71 M | 680.94 M |
{"event":"ticker_viewed","properties":{"ticker":"BIO-B","listing_kind":"stock","pathname":"/stocks/bio-b","exchange":"NYSE","country":"US"}}